Home | Reports | Startups | Press Releases | Blog | Online Store | site map


Developments

Financings

Reports

Startups
blog
Blog
Medtech podcast
Podcast

Cardiology

Surgery

Methodology

Download the report now
by purchasing online

OR

or fax us your order form

Single user price
$3,450

Tissue Engineering 2010

Tissue Engineering Worldwide Market, 2009-2018

· 314 pages   · 74 Exhibits   · 147 Company Profiles   · Report #S520   · February 2010

This report reveals in detail the status and opportunities for technologies, applications and markets in tissue engineering, cell therapy and tissue/cell transplantation. The report reviews therapeutic tissue engineering, tissue reconstruction, cell therapies, tissue/organ transplantation and related technologies under various stages of development at nearly 150 companies. The report details the technology development, projected market introduction dates and/or current and forecast market size and competitor shares for products being developed to address major causes of death and disease spanning applications in cardiovascular, neurological, orthopaedic, urological, skin, dental, ophthalmological, gastrointestinal, organ transplant, cancer and others. The report details the status of product development and assesses the current and forecast worldwide market for tissue engineering, cell therapy and transplantation. 

The report provides market size and share data, with forecast market data to 2018, for the U.S., Europe, Asia/Pacific and Rest of World.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Table of Contents

Executive Summary

Buyers of this report include:
Cell therapy companies
Tissue engineering companies
Large device multinationals
Venture capital firms
Pharma companies
Angel investors
Industry analysts/consultants

 

Section 1:      TISSUE ENGINEERING AND CELL THERAPY INDUSTRY BACKGROUND

1.1        Overview

1.2        Definitions

1.3        Growth of Key Procedures

1.4        Development Challenges

1.4.1        Material-based Tissue Replacements

1.4.2        Allograft-derived Tissue Replacements

1.4.3        Cell and Tissue Engineered Products

1.5        Unmet Clinical Needs

1.6        Business Models Based On Tissue Engineering and Cell Therapy

1.7        Timescales

1.8        Sector Challenges

1.8.1        Reimbursement

1.8.2        Regulatory

1.8.2.1        United States

1.8.2.2        China

1.8.2.3        European Union

1.8.3        Cost-effectiveness

1.8.4        Clinical Issues

1.8.5        Economic Downturns Worldwide

1.9        Competition Intensity

1.9.1        Industry Focus

1.9.2        Investment Levels

1.9.3        Investor Returns

Section 2:      Clinical Disorders and Therapy Needs

2.1        Introduction

2.1.1        Stem Cell Banking

2.1.2        Cardiovascular and Vascular

2.1.3        Coronary Heart Disease

2.1.4        Myocardial Infarction

2.1.5        Congestive Heart Failure

2.1.6        Dysfunctional Heart Valves

2.1.7        Peripheral Vascular Disorders

2.1.8        Abdominal Aortic Aneurysm

2.2        Cancer

2.2.1        Urology

2.2.1.1        Bladder

2.2.1.2        Kidney/Renal Cell

2.2.1.3        Prostate

2.2.2        Neurology

2.2.3        Ob/Gyn

2.2.3.1        Breast

2.2.3.2        Ovarian

2.2.3.3        Endometrial

2.2.3.4        Cervix Uteri

2.2.4        Orthopedic/Bone

2.2.5        Gastrointestinal/Gastroenterology

2.2.5.1        Colorectal

2.2.5.2        Gastric

2.2.5.3        Pancreas

2.2.5.4        Liver

2.2.5.5        Esophageal

2.2.6        Head and Neck

2.2.6.1        Oral

2.2.6.2        Throat

2.2.6.3        Thyroid

2.2.7        Hematopoietic

2.2.7.1        Leukemia

2.2.7.2        Lymphoma

2.2.8        Respiratory

2.2.8.1        Lung

2.2.9        Dermatology (Skin Cancer)

2.3        Dental

2.3.1        Missing Teeth

2.3.2        Periodontal Disease

2.4        ENT/Respiratory/Cardiopulmonary

2.4.1        Trachea

2.4.2        Respiratory Epithelial Cells

2.5        Gastrointestinal

2.5.1        Esophagus

2.5.2        Colon/Small Intestine

2.6        Gynecology

2.7        Neurological

2.7.1        Stroke

2.7.2        Parkinson's Disease

2.7.3        Alzheimer's Disease

2.7.4        Epilepsy

2.7.5        Traumatic Brain Injury

2.7.6        Central Nervous System and Spinal Cord Disease

2.7.6.1        Amyotrophic Lateral Sclerosis

2.7.6.2        Multiple Sclerosis

2.7.6.3        Neuromuscular/Muscular Dystrophy

2.8        Ophthalmology

2.8.1        Cornea

2.8.2        Retina

2.9     Organ Transplantation

2.9.1     Liver

2.9.2     Heart

2.9.3     Kidney

2.9.4     Pancreas

2.10     Orthopedic

2.10.1     Non-Union Fractures

2.10.2     Cartilage Damage and Repair

2.10.3     Ligament Damage

2.10.4     Vertebral Disc Damage

2.10.5     Bone Graft Materials

2.11     Skin/Integumentary

2.11.1     Burns

2.11.2     Diabetic Ulcers

2.11.3     Venous Ulcers

2.11.4     Plastic and Reconstructive Surgery

2.12     Urological

2.12.1     Incontinence

2.12.2     Kidney Disease

2.12.3     Bladder

Section 3:      Product & Company-Sponsored Technology Developments (Approved and in Development)

3.1        Introduction

3.2        Cancer

3.2.1        Types of Cancer Gene Therapies

3.2.2        Direct Delivery of Gene Proteins to Tumor

3.2.3        Medications to Boost the Immune System/Antibodies

3.2.4        Anti-Angiogenesis

3.2.5        Vaccines

3.2.6        Expanded Numbers of Cord Blood Stem Cells

3.3        Cardiovascular and Vascular

3.4        Dental

3.5        ENT/Respiratory/Cardiopulmonary

3.6        Gastrointestinal

3.7        Gynecology

3.8        Neurological

3.9        Ophthalmology

3.10     Organ Transplantation and Related Therapies

3.10.1     Liver

3.10.2     Kidney

3.10.3     Pancreas/Diabetes Therapies

3.10.4     Cryopreservation of Cells and Tissues

3.11     Orthopedic

3.12     Skin/Integumentary

3.12.1     Plastic and Reconstructive Surgery

3.13     Urological

 

Section 4:      Markets, Potential Markets, and COMPETITOR SHARES

4.1        Worldwide Potential Market for Tissue Engineered Products

4.2        Cardiovascular and Vascular

4.3        Neurological

4.4        Orthopedic

4.5        Urological

4.6        Skin/Integumentary

4.7        Dental

4.8        Organ Transplantation and Preservation

4.9        Ophthalmology

4.10     General, Gastrointestinal, Gynecologic and Other

4.11     Cancer

4.12     Cord Blood and Cell Banking

 

Section 5:      Company profiles

5.1        3DM Inc.

5.2        Aastrom Bioscience Inc.

5.3        Acorda Therapeutics Inc.

5.4        Advanced BioHealing, Inc.

5.5        Advanced Cell Technology, Inc.

5.6        Advanced Medical Solutions PLC

5.7        Aeolus Pharmaceuticals

5.8        Aldagen, Inc.

5.9        Alexion Pharmaceuticals

5.10     Angioblast Systems, Inc.

5.11     Angiotech Pharmaceuticals, Inc.

5.12     Ariad Pharmaceuticals Inc.

5.13     Arteriocyte Medical Systems, Inc.

5.14     Athersys, Inc.

5.15     Avax Technologies Inc.

5.16     Avita Medical Limited

5.17     Baxter International Inc.

5.18     BeFutur Biotechnologies

5.19     Bio Nova International

5.20     Biocomposites

5.21     Biocoral Inc.

5.22     Bioheart Inc.

5.23     BioHybrid Technologies

5.24     BioLife Solutions Inc.

5.25     Biomet, Inc.

5.26     BioMimetic Therapeutics

5.27     BioSante Pharmaceuticals, Inc.

5.28     BioSyntech

5.29     BioTissue Technologies GmbH

5.30     Boston Scientific Corporation

5.31     BrainStorm Cell Therapeutics, Inc.

5.32     Breonics Perfusion Technologies, Inc.

5.33     BTG International Ltd.

5.34     California Stem Cells Inc.

5.35     Capstone Therapeutics

5.36     Celgene Corporation

5.37     CellECT Bio Inc.

5.38     Cellerix SA

5.39     CellSeed, Inc.

5.40     CellTran Ltd.

5.41     Cellular Dynamics International

5.42     Centocor Ortho Biotech, Inc.

5.43     Cerco Medical

5.44     co.don AG

5.45     ConMed Linvatec

5.46     Cook Group

5.47     CorCell Companies, Inc.

5.48     Cryo-Cell International, Inc.

5.49     CryoLife, Inc.

5.50     Curis Inc.

5.51     Cyclacel Pharmaceuticals, Inc.

5.52     Cytograft Tissue Engineering

5.53     Cytomatrix LLC

5.54     Cytori Therapeutics Inc.

5.55     ES Cell International

5.56     Exactech, Inc.

5.57     Excorp Medical, Inc.

5.58     FibroGen, Inc.

5.59     Fidia Advanced Biopolymers/Anika Therapeutics, Inc.

5.60     Forticell Bioscience, Inc.

5.61     Gamida Cell Ltd.

5.62     Garnet BioTherapeutics

5.63     Genta, Inc.

5.64     GenVec, Inc.

5.65     Genzyme Corporation

5.66     Geron Corporation

5.67     Glycotex, Inc.

5.68     HepaLife Technologies, Inc.

5.69     Hospira

5.70     Humacyte, Inc.

5.71     InCytu Inc.

5.72     Inion Ltd.

5.73     Innogenetics

5.74     InnovaCell Biotechnologie GmbH

5.75     Integra LifeSciences Inc.

5.76     ISTO Technologies Inc.

5.77     Johnson & Johnson Inc.

5.77.1     Ethicon Biosurgery

5.77.2     DePuy

5.78     Kensey Nash

5.79     Kerecis EHF

5.80     LifeCell Inc.

5.81     LifeStem Inc. (Calba Tech, Inc.)

5.82     Living Cell Technologies Ltd.

5.83     Lonza Group Ltd.

5.84     MaxCyte

5.85     Medtronic

5.86     Mesoblast Limited

5.87     MG Biotherapeutics, LLC

5.88     MicroIslet Inc.

5.89     Miltenyi Biotec

5.90     Musculoskeletal Transplant Foundation

5.91     Natural Implant

5.92     NellOne Therapeutics, Inc.

5.93     NeoStem, Inc.

5.94     Neuralstem, Inc.

5.95     NeuroGeneration, Inc.

5.96     NeuroNova AB

5.97     Neurotech

5.98     Novartis International AG

5.99     Novo Nordisk A/B

5.100     OncoMed Pharmaceuticals

5.101     Organogenesis Inc.

5.102     Organovo, Inc.

5.103     Orthovita

5.104     OSI Pharmaceuticals

5.105     Osiris Therapeutics Inc.

5.106     Osteotech, Inc.

5.107     Pioneer Surgical Technologies

5.108     Pluristem Therapeutics Inc.

5.109     Poly-Med, Inc.

5.110     Polyganics BV

5.111     ProChon Biotech, Ltd.

5.112     Progenitor Cell Therapy Inc.

5.113     ProNeuron Biotechnologies, Inc.

5.114     Protein Polymer Technologies Inc.

5.115     ReGen Biologics Inc.

5.116     Reinnervate Ltd.

5.117     ReNeuron Ltd.

5.118     Revivicor, Inc.

5.119     RTI Biologics, Inc.

5.120     Sanofi-Aventis

5.121     Sciperio Inc.

5.122     Serica Technologies, Inc./Allergan

5.123     Sernova Corp.

5.124     Smith & Nephew Ltd.

5.125     SpineSmith Partners, LP

5.126     Stem Cell Pharma Inc.

5.127     Stem Cell Sciences UK Ltd.

5.128     Stem Cell Therapy International, Inc./Histostem Co. Ltd.

5.129     StemCell Technologies Inc.

5.130     StemCells Inc.

5.131     Stryker Corporation

5.132     Synovis Life Technologies, Inc.

5.133     Targeted Genetics Corporation

5.134     TEI Biosciences Inc.

5.135     Tengion, Inc   .

5.136     Tepha Inc.

5.137     Theracell, Inc.

5.138     ThermoGenesis Corp.

5.139     TiGenix N.V.

5.140     Transition Therapeutics Inc.

5.141     TriStem Corporation

5.142     Vesta Therapeutics

5.143     ViaCell/PerkinElmer

5.144     ViaCyte, Inc. (formerly, Novocell, Inc.)

5.145     Vital Therapies, Inc.

5.146     Vitrolife AB

5.147     Zimmer, Inc.

 

Appendix:  Company Directory

 

 

List of Exhibits

 

Exhibit ES-1:  Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018

Exhibit ES-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018

Exhibit ES-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018

Exhibi ES-4:  Worldwide Tissue Engineering & Cell Therapy Market by Manufacturer, 2009

 

Exhibit 2-1: Leading Companies in Stem Cell Banking

Exhibit 2-2: Potential For Cardiovascular Tissue Engineering — Incidences of Applicable Surgical Procedures, 2010

Exhibit 2-3: Prevalence of Cardiovascular Disease in Adults Age 20 and Older by Age and Sex, Percent of the Population, 2003–2006

Exhibit 2-4: Incidence of Cardiovascular Disease by Age and Sex, Per 1,000 Person Years, 1980–2003

Exhibit 2-5: Incidence of Myocardial Infarction by Age and Sex, 1987–2004

Exhibit 2-6: Prevalence of Heart Failure in the United States by Age and Sex, Percent of Population

Exhibit 2-7: Incidence of New Cancer Cases Worldwide by Region, 2007

Exhibit 2-8: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S., 2002–2006, Rate per 100,000

Exhibit 2-9: Colorectal Cancer Incidence and Mortality Rates by Race/Ethnicity and Sex in the U.S., 2001–2005, Rate per 100,000

 

Exhibit 3-1: Companies with Cancer Therapies Marketed or in Development

Exhibit 3-2: Key Competitors in Tissue Engineering and Cell Therapies for Cardiovascular Applications

Exhibit 3-3: Key Competitors in Tissue Engineering and Cell Therapies for Dental and Oral Surgery Applications

Exhibit 3-4: Key Competitors in Tissue Engineering and Cell Therapies for ENT, Respiratory and Cardiopulmonary Applications

Exhibit 3-5: Key Competitors in Tissue Engineering and Cell Therapies for Gastrointestinal Applications

Exhibit 3-6: Key Competitors in Tissue Engineering and Cell Therapies for Gynecology Applications

Exhibit 3-7: Key Competitors in Tissue Engineering and Cell Therapies for Neurology Applications

Exhibit 3-8: Key Competitors in Tissue Engineering and Cell Therapies for Ophthalmology Applications

Exhibit 3-9: Key Competitors in Tissue Engineering and Cell Therapies for Organ Transplant, Organ Preservation and Related Therapies

Exhibit 3-10: Key Competitors in Tissue Engineering and Cell Therapies for Orthopedic, Musculoskeletal, and Spine Applications

Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Skin/Integumentary Applications

Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Urological Applications

 

Exhibit 4-1:  Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018

Exhibit 4-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018

Exhibit 4-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018

Exhibit 4-4: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, 2009-2018

Exhibit 4-5: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Geographic Segment, 2009-2018

Exhibit 4-6: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Manufacturer, 2009

Exhibit 4-7: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, 2009-2018

Exhibit 4-8: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Geographic Segment, 2009-2018

Exhibit 4-9: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Manufacturer, 2009

Exhibit 4-10: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, 2009-2018

Exhibit 4-11: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Geographic Segment, 2009-2018

Exhibit 4-12: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Manufacturer, 2009

Exhibit 4-13: Worldwide Tissue Engineering & Cell Therapy Market, Urology, 2009-2018

Exhibit 4-14: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Geographic Segment, 2009-2018

Exhibit 4-15: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Manufacturer, 2009

Exhibit 4-16: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, 2009-2018

Exhibit 4-17: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Geographic Segment, 2009-2018

Exhibit 4-18: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Manufacturer, 2009

Exhibit 4-19: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, 2009-2018

Exhibit 4-20: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Geographic Segment, 2009-2018

Exhibit 4-21: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Manufacturer, 2009

Exhibit 4-22: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, 2009-2018

Exhibit 4-23: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Geographic Segment, 2009-2018

Exhibit 4-24: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Manufacturer, 2009

Exhibit 4-25: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, 2009-2018

Exhibit 4-26: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Geographic Segment, 2009-2018

Exhibit 4-27: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Manufacturer, 2009

Exhibit 4-28: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, 2009-2018

Exhibit 4-29: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, by Geographic Segment, 2009-2018

Exhibit 4-30: Worldwide Tissue Engineering & Cell Therapy Market, General, GI, Gyn, Others, by Manufacturer, 2009

Exhibit 4-31: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, 2009-2018

Exhibit 4-32: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Geographic Segment, 2009-2018

Exhibit 4-33: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Manufacturer, 2009

Exhibit 4-34: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, 2009-2018

Exhibit 4-35: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Geographic Segment, 2009-2018

Exhibit 4-36: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Manufacturer, 2009

 

Exhibit 5-1: Advanced Cell Technology, Inc. and Subsidiary Consolidated Statements of Operations for the Years Ended December 31, 2008 and 2007

Exhibit 5-2: Clinical Trials Being Conducted by Mesoblast and Angioblast

Exhibit 5-3: Angioblast’s Lead Products in Development

Exhibit 5-4: Baxter Sales by Business, 2008, $ Billions

Exhibit 5-5: BTG International’s Revenue-Producing Products and Sales Data

Exhibit 5-6: Celgene’s Leading Product Candidates

Exhibit 5-7: CryoLife Revenue by Product, 2008

Exhibit 5-8: Genzyme Approved/Marketed Cell Therapy–Derived Products

Exhibit 5-9: Geron’s hESC-derived Product Candidates

Exhibit 5-10: Osteotech Revenues, Year End 2006–2008 (000)

Exhibit 5-11: Proneuron’s Developmental Product Pipeline

Exhibit 5-12: RTI Biologics’ Revenues, Years Ended Dec. 31, 2006–2008, (000)

Exhibit 5-13: RTI Biologics’ Products by Distributor

Exhibit 5-14: TEI Biosciences’ Products, Applications and Marketing Partners

 

Request a report sample by emailing request to:

 


 

Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018.  (Published February 2010)

 

Price:  $3,450 (print or PDF; add $200 for both).  Site/Global License also available.

 

Purchase for immediate PDF download via online store (PDF and other options also below) or fax us your order form..

REPORT: Tissue/Cell 2010 PDF -- $3,450.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

REPORT: Tissue/Cell 2010 Print -- $3,450.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

REPORT: Tissue/Cell 2010 PDF and Print -- $3,650.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

REPORT: Tissue/Cell 2010 Site License -- $4,950.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

REPORT: Tissue/Cell 2010 Global License -- $5,950.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

 

 

Methodology.
MedMarket Diligence Reports are produced through primary and secondary research. Primary research includes interviews with clinicians and industry representatives for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary research includes gathering data from published sources (annual reports, Securities and Exchange Commission 10K, 10Q and other regulatory filings, federal/state/international datasets, company literature, others) on products and technologies on the market and under development. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

 

Contact: Patrick Driscoll, patrick <at> mediligence <dot> com. Tel: (949) 859-3401.

Copyright © 2010 MedMarket Diligence, LLC. All rights reserved.
Revised: 02/16/11

 

 

 

 

 

 

 

Or call
+1.949.891.1753

+1.949.859.3401
+1.949.837.4558 fax
1.866.820.1357 toll-free (US)

 

 
Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports

 

White Paper
High Growth
Medical Technologies

October 2009

 

 

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us